Pharmaceuticals manufacturer Aspen’s wholly-owned Mauritius-incorporated subsidiary Aspen Global Incorporated (AGI) has concluded an agreement in terms of which Mylan Ireland will acquire the commercialisation rights and related intellectual property of Aspen’s Thrombosis business in Europe for €641.9-million, plus the cost of the related inventory. In March 2019, Aspen announced that it would undertake a strategic review in respect of its Europe CIS Commercial business. The review has focused on assessing alternative models for the conduct of the business and in determining the range of available options with a view to enhancing the group’s sustainable returns.
from Engineering News | Home https://ift.tt/3h6V8EN
